Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Chemicals Specialty Chemicals
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Ceapro Inc > Value to shareholders
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(25)
•••
Comment by winnerswingon Apr 13, 2023 9:37am
48 Views
Post# 35392680

RE:RE:RE:RE:Value to shareholders

RE:RE:RE:RE:Value to shareholders
prophetoffactz wrote:
winnerswing wrote: No, I mean value created from Q3 2022 to Q4 2022: the shareholder value creation from the good 2022 year is already included in the Q3 results.


Stocks aren't valued on the basis of a single quarter. Stocks are valued based on the next 10 years into the future, etc. Ignore a given quarter. One quarter in the next ten years is only 2.5% of the stocks value, in a sense.  

Q4 is typically the weakest quarter. Individual quarters are lumpy. You need to look at annual results. 2022 was another record year with 10% growth which is consistent with the historic growth rate of the last decade. 
  • "Cash generated from operations of $6,637,000, for the full year 2022 compared to $3,510,000 in 2021." News release
The pipeline continues to advance from approval for the avenanthramide clinical trial, to the fibrosis drug which is before a go/no go clinical trial decision in the summer. The bioavailability results were also exceptional vs. the gold standard.  
 


You know what I mean...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities